Listed D-1 SK Basa… Securities market “good supply and demand conditions are expected,”

Input 2021.03.17 11:23

The stock price is 169,000 won on the 18th
Due to the high proportion of commitments, institutional sales are likely to be small

SK Bioscience’s listing on the stock market, which was the largest ever margin of KRW 63.6 trillion in subscription stocks, is approaching one day ahead. The financial investment industry predicts that SK Bioscience will be able to’blow the price’ in which SK Bioscience doubles the public offering price on the first day and forms an initial price, and then increases to the upper limit and closes.

If SK Bioscience succeeds, the company’s stock price will be 169,000 won. The public offering is 104,000 won higher than 65,000 won, and the rate of return is 160%.

On the 17th, Park Byeong-gi, head of the corporate finance division of Hana Financial Investment, said, “In the past, companies that had high competition rates for institutional demand forecasts and public offerings had a good share price after listing,” he said. “SK Bioscience is expected to follow this trend.” Like SK Biopharm and Kakao Games, who entered the stock market last year, it is predicted that SK Bioscience will be able to do so.

SK Biopharm, which started trading on July 2 of last year, had an offering price of 49,000 won, but the initial price of the transaction soared to 98,000 won and the closing price of 127,000 won. SK Biopharm recorded the upper limit for 3 consecutive trading days from the date of listing. Kakao Games also started trading at 48,000 won on September 10 last year, the date of listing, and rose to 62,400 won. Kakao Games continued its upper limit march on the 11th, the next day. The public offering price was 24,000 won.

The financial investment industry in particular paid attention to the supply and demand of SK Bioscience. It means that whether or not it is achieved depends on supply and demand. Supply and demand is a stock market term that refers to supply and demand, and refers to how much individual investors, institutional investors, and foreign investors offer to sell and buy.

Looking at the supply and demand of SK Bioscience, 85.3% of the 12.622,500 shares allocated to institutions among public offering stocks are committed stocks that cannot be sold on the date of listing. Obligatory retention commitment refers to a promise not to sell for a certain period of time after listing when a public offering stock is allocated.

In terms of the percentage of institutional investors, SK Bioscience is more than 10% more than SK Biopharm (52.3%) and Kakao Games (72.6%). This means that institutional investors are more likely to raise the stock price as they offer less sales.

An official from the financial investment industry said, “The stock price of bio companies is so difficult to predict, and what will happen to the supply and demand greatly affects the stock price.”

Aureum Asset Management Fund Manager Kwak Ju-hee also said, “It cannot be said that the stock price is secured by a large number of institutional obligations, but since it is a large stock in the bio sector and its subscription margin recorded a record high, it is worth paying attention to the stock price trend after listing.” .

Byunghwa Han Eugene Investment & Securities (001200)The researcher explained, “It is a fixed fact that SK Bioscience’s performance will grow significantly this year,” he said. “At the beginning of the listing, there is not much circulation, so we expect the stock price to form from 16 trillion won to 25 trillion won based on the market capitalization.” .